Effectiveness of the XBB.1.5 COVID‐19 Vaccines Against SARS‐CoV‐2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024
We estimated the effectiveness of the adapted monovalent XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation during the BA.2.86/JN.1 lineage-predominant period using a multicentre test-negative case-control study in Europe. We included older adults (≥ 65 years) hospitalised with severe acute respiratory infection from November 2023 to May 2024. Vaccine effectiveness was 46% at 14-59 days and 34% at 60-119 days, with no effect thereafter. The XBB.1.5 COVID-19 vaccines conferred protection against BA.2.86 lineage hospitalisation in the first 4 months post-vaccination.
Authors
- Marcos Iglesias (ORCID: https://orcid.org/0000-0002-7523-5950)
- Mihaela Lazăr (ORCID: https://orcid.org/0000-0002-8226-6026)
- Jesús Castilla
- Petr Husa (ORCID: https://orcid.org/0000-0002-9190-2610)
- Verónica Gomez (ORCID: https://orcid.org/0000-0003-0485-0005)
- Nuno Verdasca (ORCID: https://orcid.org/0000-0002-4673-5411)
- Liliana Antunes (ORCID: https://orcid.org/0000-0003-0453-5304)
- Zvjezdana Lovrić Makarić (ORCID: https://orcid.org/0000-0003-4285-2116)
- Gergő Túri (ORCID: https://orcid.org/0000-0003-3465-8321)
- Goranka Petrović (ORCID: https://orcid.org/0000-0001-8304-5519)
- Isabel Leroux‐Roels (ORCID: https://orcid.org/0000-0002-5084-4696)
- Maria‐Louise Borg (ORCID: https://orcid.org/0000-0001-8961-9413)
- Madelyn Yiseth Rojas Castro (ORCID: https://orcid.org/0000-0001-7006-7946)
- Luca Basile (ORCID: https://orcid.org/0000-0002-4707-2621)
- Alexandru Marin (ORCID: https://orcid.org/0009-0000-7668-9607)
- Lenka Součková (ORCID: https://orcid.org/0000-0003-0028-4464)
- Beatrix Oroszi (ORCID: https://orcid.org/0000-0001-8915-0336)
- Aušra Džiugytė (ORCID: https://orcid.org/0000-0003-0486-8491)
- Ralf Dürrwald (ORCID: https://orcid.org/0000-0002-3432-0438)
- Monika Kuliešė (ORCID: https://orcid.org/0000-0002-4601-4585)
- Sabrina Bacci (ORCID: https://orcid.org/0000-0002-6575-3439)
- Ausenda Machado (ORCID: https://orcid.org/0000-0002-1849-1499)
- Nathalie Nicolay (ORCID: https://orcid.org/0000-0002-5916-7855)
- Jennifer Howard (ORCID: https://orcid.org/0009-0008-1930-8693)
- Angela MC Rose (ORCID: https://orcid.org/0000-0002-2493-8082)
- Carolin Hackmann (ORCID: https://orcid.org/0000-0001-8788-3632)
- Ligita Jančorienė (ORCID: https://orcid.org/0000-0001-6488-6312)
- Margaret G. Fitzgerald (ORCID: https://orcid.org/0000-0002-4535-0966)
- Róisín Duffy (ORCID: https://orcid.org/0009-0001-7169-9109)
- Iván Martínez‐Baz
- Silke Ternest
Institutions
- Semmelweis University (HU)
- Lithuanian University of Health Sciences (LT)
- Generalitat de Catalunya (ES)
- Vilnius University (LT)
- Masaryk University (CZ)
- Robert Koch Institute (DE)
- Ghent University Hospital (BE)
- Instituto de Salud Carlos III (ES)
- Health Service Executive (IE)
- Instituto de Salud Pública de Navarra (ES)
- Hrvatski zavod za javno zdravstvo (HR)
- University Hospital Brno (CZ)
- Institutul Cantacuzino (RO)
- Health Protection Surveillance Centre (IE)
- Spitalul Clinic Dr. Victor Babes (RO)
- National Institute of Health Dr. Ricardo Jorge (PT)
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (ES)
- European Centre for Disease Prevention and Control (SE)
Publication Details
- Journal
- Influenza and Other Respiratory Viruses
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1111/irv.70081
- Citations
- 10
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 13.96
Funders
- European Centre for Disease Prevention and Control